Scarica l'app Stockscreener
130.71
0.46%
-0.61
Pre-mercato:
129.03
-1.68
-1.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$131.32
Aprire:
$132.37
Volume 24 ore:
1.76M
Relative Volume:
1.20
Capitalizzazione di mercato:
$19.04B
Reddito:
$9.61B
Utile/perdita netta:
$1.62B
Rapporto P/E:
11.81
EPS:
11.07
Flusso di cassa netto:
$1.77B
1 W Prestazione:
-6.86%
1M Prestazione:
-7.76%
6M Prestazione:
-29.26%
1 anno Prestazione:
-36.67%
Intervallo 1D:
$130.05
$133.77
Intervallo di 1 settimana:
$128.75
$141.25
Portata 52W:
$128.51
$238.00
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Confronta BIIB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
130.71 | 19.04B | 9.61B | 1.62B | 1.77B | 11.07 |
|
LLY
Lilly Eli Co
|
789.09 | 708.74B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
201.64 | 356.70B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
159.82 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
67.10 | 297.86B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
112.26 | 221.72B | 51.72B | 11.94B | 13.81B | 5.88 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
United Bank Sells 2,213 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Stock Position Lowered by Groupama Asset Managment - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Purchased by B. Metzler seel. Sohn & Co. AG - MarketBeat
Korea Investment CORP Reduces Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
DnB Asset Management AS Has $7.26 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Saratoga Research & Investment Management Sells 149,272 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Norges Bank Makes New $355.57 Million Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Mitsubishi UFJ Asset Management Co. Ltd. Increases Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Level Four Advisory Services LLC Has $1.14 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationBIIB - ACCESS Newswire
Biogen Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your RightsBIIB - ACCESS Newswire
Biogen (NasdaqGS:BIIB) Gets US FDA Fast Track For Alzheimer's Despite US$8M Settlement - simplywall.st
May 23rd Options Now Available For Biogen (BIIB) - Nasdaq
BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag - Nasdaq
RBC Capital cuts Biogen stock price target to $221 - Investing.com India
California Public Employees Retirement System Has $60.84 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Sei Investments Co. - MarketBeat
Beutel Goodman & Co Ltd. Purchases 2,323 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen (NASDAQ:BIIB) Shares Acquired Rep. Robert Bresnahan, Jr. - MarketBeat
Biogen (BIIB) Gains FDA Fast Track for Alzheimer's Therapy - GuruFocus
Biogen’s tau targeting Alzheimer’s disease therapy gets FDA Fast Track status - MSN
Leqembi’s EU review drags on; Sanofi gets a new development head - BioPharma Dive
Organon acquires Actemra biosimilar’s US rights from Biogen - Yahoo Finance
Biogen’s BIIB080 gains FDA fast track for Alzheimer’s By Investing.com - Investing.com Australia
Biogen’s BIIB080 gains FDA fast track for Alzheimer’s - Investing.com India
Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease - The Manila Times
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease - Biogen
Breakthrough: Biogen's First-of-its-Kind Alzheimer's Drug Gains FDA Fast Track Status - Stock Titan
Organon Looks To Tap Tocilizumab Potential Following Biogen Acquisition - insights.citeline.com
Headlands Technologies LLC Buys 27,129 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
4,298 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Allstate Corp - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Stock Holdings Decreased by Wellington Management Group LLP - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Shares Sold by American Century Companies Inc. - MarketBeat
Immunomodulators Market Set to Witness Significant Growth - openPR.com
Organon Expands Biosimilar Portfolio With Tofidence Acquisition - Managed Healthcare Executive
Multiple Sclerosis Pipeline 2025: Key Companies, MOA, ROA, - openPR.com
Biogen Inc. stock outperforms competitors despite losses on the day - MSN
Biogen Says Investigational Alzheimer's Drug Receives FDA Fast Track Designation - MarketScreener
FDA-Approved Biosimilars Market: A Complete List & Latest - openPR.com
Organon buys rights to Biogen’s biosimilar targeting Roche’s Actemra - Seeking Alpha
Organon acquires US rights to arthritis biosimilar TOFIDENCE - Investing.com India
Organon acquires US rights to arthritis biosimilar TOFIDENCE By Investing.com - Investing.com Australia
Organon Claims US Market Leadership with Groundbreaking Tocilizumab Biosimilar Deal - Stock Titan
EC refers lecanemab decision to Appeal Committee - The Pharma Letter
Biogen (NASDAQ:BIIB) sheds US$697m, company earnings and investor returns have been trending downwards for past five years - Yahoo Finance
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission - Biogen
Thrivent Financial for Lutherans Has $2.42 Million Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
The US Approved an Alzheimer's Drug. Seven Patients Subsequently Died - Bloomberg
The US approved an Alzheimer’s drug. Seven patients subsequently died. - The Boston Globe
Mitsubishi UFJ Trust & Banking Corp Increases Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.24%
1.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):